In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Andrew McConaghie

Senior Writer

Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.

He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.

Latest From Andrew McConaghie

Merck To Pay Up To $425m For Foghorn’s Gene Regulation Therapies

US major continues its expansion in oncology with an early stage deal with Flagship Pioneering protegés.

Commercial Companies

‘Agile’ Approach Aims To Accelerate Ridgeback’s COVID-19 Timeline

The Bayesian adaptive trial design is looking to slash development times, starting with a Phase II trial of Ridgeback’s drug, a potential challenger to Gilead’s remdesivir.

Companies Commercial

Operation Warp Speed Spreads Its Bets With $1.6bn Novavax Deal

Novavax has progressed into Phase I trials with relatively little funding, but backing from Operation Warp Speed makes it a stronger contender.

Companies Commercial

UK Uses Local Outbreak Data To Target Coronavirus Vaccine Trials

The UK Vaccine Taskforce is helping to troubleshoot for COVID-19 candidates including in clinical trials and manufacturing scale-up.

Clinical Trials Coronavirus COVID-19

EU Approves Gilead’s Remdesivir For COVID-19 In Record Time

The EU has granted conditional marketing approval to Gilead’s drug, which has the brand name Veklury. It will cost about 2,000 per treatment.

Europe Approvals

Amid Supply Concerns, EU Approves Gilead’s Remdesivir

Europe has granted a conditional approval to Gilead’s drug, now named Veklury, costing 2,000 per treatment.

See All
UsernamePublicRestriction

Register